OR WAIT null SECS
NGS abbreviates drug discovery timelines.
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
Developing cell-based potency assays for cell therapies requires meticulous coordination.
December 08, 2023
MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.
December 01, 2023
Sufficient stability studies show a drug product meets regulatory requirements, therefore ensuring the drug reaches the patients who rely on it.
November 29, 2023
TAU Systems plans to establish TAU Labs, a new next-generation, laser-driven plasma accelerator laboratory, in Carlsbad, Calif.
Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.
November 27, 2023
MilliporeSigma has expanded its biosafety testing laboratories in Shanghai, China, with the completion of new lab space at its new €29 million (US$43 million) Biologics Testing Center.
November 20, 2023
Webinar Date/Time: Wed, Dec 13, 2023 10:00 AM EST
November 16, 2023
Twist Bioscience now offers its Express Genes rapid gene synthesis service at its Wilsonville, Ore., manufacturing facility.
Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.
November 15, 2023
The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio.
Webinar Date/Time: Tuesday, December 12, 2023 Session 1: 9:00 am EDT | 1:00pm GMT | 2:00pm CET Session 2: 1:00 pm EDT| 12:00pm CDT| 10:00am PDT